Objectives: Cisplatin remains the pivotal chemotherapy in squamous cell carcinoma of the head and neck (SCCHN), with nephrotoxicity considered the dose-limiting toxicity. The purpose of our study was to propose an outpatient high-dose cisplatin protocol aimed at preventing nephrotoxicity and to analyze the results of its utilization in patients with SCCHN treated with concurrent radiotherapy.
C oncurrent chemoradiotherapy (CRT) is considered standard treatment for patients with squamous cell carcinoma of the head and neck (SCCHN). Cisplatin remains the mainstay chemotherapeutic agent, preferentially involving high-dose cisplatin (HD-cis). [1] [2] [3] Added to radiotherapy (RT), cisplatin increases the incidence of acute and long-term toxicities, with nephrotoxicity being the drug-specific and dose-limiting adverse effect. [4] [5] [6] [7] Cisplatin concentration is reportedly 5 times higher in the kidneys than in blood, 8, 9 affecting ion and water transporters. 10 Patients experience polyuria, degrees of salt-wasting, hypomagnesemia, hypokalemia, hypotension, and consequently decreased creatinine (Cr) clearance. 8, [11] [12] [13] [14] Volume expansion with isotonic saline infusion and electrolyte replacement is the most effective preventive strategy. [8] [9] [10] [15] [16] [17] [18] The FDA-regulated cisplatin approval document recommends aggressive fluid resuscitation of 1 to 2 L 0.9% saline infused over 8 to 12 hours before cisplatin, followed by oral hydration to maintain adequate urine output over next 24 hours. 8, 19 Historically, patients were hospitalized for cisplatin administration. Current practice is to administer HD-cis as outpatient high-dose cisplatin (op-HD-cis). This has been facilitated by the development of potent antiemetics.
Controversy remains over outpatient schedule and optimal dose and duration of fluid and electrolytes replacement. Few publications are available presenting outpatient cisplatin regimens. 9, [19] [20] [21] Tiseo and colleagues showed that outpatient HD-cis was safe with short-term hydration (2 L isotonic saline over 4 h) in patients with lung cancer. This issue remains unaddressed in patients with SCCHN undergoing CRT. This is of distinct importance, as maintaining adequate hydration is difficult in this patient population. CRT of the head and neck causes mucositis, dysphagia, and nausea, which significantly limit oral hydration, increasing risk of nephrotoxicity. Consequently, there is a trend in current practice toward using more fractionated schedules for cisplatin administration (weekly, daily), although not tested in large clinical trials. We developed a protocol for op-HD-cis that involved preventive saline hydration and electrolyte replacement for the first 96 hours after cisplatin, the timeframe most critical in acute kidney injury (AKI) prevention. 14, 19, 22 In addition, our regimen utilized patients' daily visits for RT for careful monitoring of renal and electrolyte parameters with replacement as needed.
Developing protocols aimed at preventing nephrotoxicity is challenging, with few published protocols described in sufficient detail for comparison and inconsistent methods of analyzing nephrotoxicity. In this retrospective study, we (1) described the administration of fluid and electrolyte resuscitation per our institutional protocol in patients with SCCHN receiving concurrent RT and op-HD-cis; (2) analyzed the incidence of AKI, electrolyte abnormalities, and chronic kidney disease (CKD); and (3) identified factors associated with development of AKI and CKD.
MATERIALS AND METHODS

Study Design
This retrospective analysis was approved by our Institutional Review Board. All consecutive patients with SCCHN treated with op-HD-cis according to our protocol concurrent with primary or adjuvant RT between January 2008 and September 2012 were identified in our cancer registry. HD-cis was defined as Z75 mg/m 2 . Patients who received at least 1 administration of op-HD-cis concurrent with RT were analyzed for AKI. Adjuvant chemotherapy was allowed for this subanalysis. Patients who received at least 2 administrations of op-HD-cis concurrent with RT, no induction or adjuvant chemotherapy, and had a minimum follow-up of 3 months were analyzed for CKD.
Op-HD-Cis Regimen
The op-HD-cis protocol is summarized in Table 1 . Op-HD-cis was administered every 3 weeks starting with day 1 of RT. Adjuvant RT was given at 60 to 66 Gy over 6 to 6.5 weeks. Definitive RT was given at 70 Gy over 7 weeks. Normal estimated glomerular filtration rate (eGFR) calculated by standard laboratory formula (IDMS traceable MDR) was ensured before treatment. Prehydration with 1000 mL normal saline (NS) over 1 to 2 hours was administered to establish euvolemia before CRT. 22 Cisplatin was then infused at a target dose of 100 mg/m 2 in 500 mL of 0.45% NS with 12.5 g of mannitol. Starting in 2012, mannitol was not administered due to drug shortage. No other diuretic was used. Cisplatin dose was calculated using actual body weight per ASCO guidelines. The posthydration regimen consisted of 1000 mL NS containing 20 mEq of potassium chloride and 16 mEq of magnesium sulfate. Patients returned to receive 1500 mL NS on day 2 and on days 3 or 4 postcisplatin treatment, with electrolyte replacement as needed based on basic metabolic panel and magnesium (Mg) levels. In rare instances of scheduling conflicts (ie, weekends), patients were encouraged to maintain adequate fluid intake until first available visit. Fosaprepitant and decadron were given as supportive medications to all patients. A 5-HT 3 antagonist (Ondansetron) was prescribed as needed. Patients were encouraged to maintain adequate fluid intake and returned to clinic weekly for physical examination and blood tests. Electrolytes were replaced as needed and additional hydration was given if patients showed signs of hypovolemia, were unable to maintain adequate fluid intake, or had increased blood urea nitrogen/Cr ratio (BUN/Cr)Z20. Patients were called for additional hydration visits when AKI was diagnosed. Cisplatin was adjusted (discontinued, delayed, or dose decreased), depending on severity of AKI, recovery, and patient compliance.
Retrospective Data Collection
The following electronic medical records data were recorded: age at SCCHN diagnosis, sex, race, tobacco use, TNM stage, highest grade of mucositis, body mass index (BMI), history of hypertension or diabetes mellitus, statin use, cumulative cisplatin dose, total amount of fluid and electrolyte replacement, serum Cr (SCr) before each dose of op-HD-cis (baseline) and posttreatment (days 2, 3, or 4), and maximum SCr level for each cycle. Other laboratory parameters included nadir serum Mg, sodium (Na), potassium (K), and BUN/ CrZ20 for each cycle. SCr level at 1 year ( ± 4 mo) and last available value, and serum Mg, K, and Na levels at 6 months were noted. Patient weights were recorded at start, end, and 3 months after CRT. Patients were considered smokers (current or recent) if they were actively smoking, or had more than a 10 pack-year history and had quit <1 year before diagnosis.
Definition of AKI and CKD
SCr rather than Cr clearance was used to measure AKI because of significant changes in weight before, during, and immediately after treatment. Cisplatin-related AKI was defined based on peak SCr after each op-HD-cis administration. AKI was staged according to Kidney Disease Improving Global Outcomes (KDIGO) criteria 23 : 0: Cr < 1.5 Âbaseline; 1: Cr = 1.5 to 1.9Â baseline; 2: Cr = 2.0 to 2.9 Âbaseline; 3: CrZ3.0Âbaseline.
CKD was measured according to KDIGO Hydration and electrolytes replacement as needed defined as decline of Z25% from baseline. CKD and eGFR drop were evaluated at 2 timepoints: (1) a fixed timepoint of 1 year ( ± 4 mo), which allowed stabilization of kidney function posttreatment, and (2) at last follow-up visit available for each patient, capturing the entire study population. Only patients with follow-up of at least 3 months were included in the study, per KDIGO criteria for chronicity. 24 
Statistical Analysis
Descriptive statistics were calculated, including means and SDs for continuous variables and counts and percentages for categorical variables. AKI was classified as KDIGO stage 1 or higher and defined by time of occurrence: cycle 1, cycle 2, or any time during treatment. Patients with versus without AKI were compared using 2-sample t tests for continuous variables and the Fisher exact tests for categorical variables. CKD was examined by percent change in eGFR (REL-eGFR) at 1 year and at last follow-up relative to baseline. For categorical variables, REL-eGFR was compared using 2-sample t tests, and Pearson correlations were used for continuous variables. For comparisons made using the last follow-up visit, REL-eGFR was modeled adjusting for the timepoint of measurement. For comparisons of categorical variables, analysis of covariance was used with time included as a covariate, and for comparisons using continuous variables, Pearson correlations were calculated adjusting for time. Electrolyte changes during treatment and at 6 months were examined for patients treated with at least 2 cycles of cisplatin using paired t tests. All analyses were performed using SAS Version 9.3 (Cary, NC).
RESULTS
Patient Characteristics
Eighty-two patients received at least 1 cycle of op-HD-cis and were analyzed for AKI. Seventy-one patients received at least 2 cycles of op-HD-cis and thus qualified for CKD analysis; however, 3 patients were excluded because they received adjuvant chemotherapy with cisplatin (Supplemental Digital Content 2, http://links.lww.com/AJCO/A127; Fig. 1 ). Patient demographics and clinical characteristics are summarized in Table 2 . Thirty-three patients (40%) had deviations from scheduled op-HD-cis, with only 6.1% involving AKI. Other reasons included neutropenia (14.6%), mucositis (7.3%), noncompliance, vomiting, and weight loss (Supplemental Digital Content 3, http://links.lww.com/AJCO/A128; Table 2 ). Patients with baseline low SCr and high eGFR had significantly lower weight (P < 0.0001 and 0.02) and BMI (P = 0.0001 and 0.006).
AKI Analysis
Any AKI Event During Treatment
Of the 82 patients, 13% received 1 cycle, 63% 2 cycles, and 23% 3 cycles of op-HD-cis (Supplemental Digital Content 2, http://links.lww.com/AJCO/A127; Fig. 1 ). Thirty-four percent developed AKI in at least 1 cycle. Three patients developed AKI after both first and second cycles of op-HD-cis. Twenty-one percent had SCr above upper limits of normal (> 1.5 mg/dL) in at least 1 cycle (Table 2 ). Figure 1A depicts the distribution of maximum SCr relative to baseline SCr for each patient and cycle. Relative to those who did not develop AKI, patients with AKI had significantly lower baseline SCr (0.9 vs. 0.78, P = 0.002), higher initial eGFR (91.3 vs. 99.9, P = 0.01), were more often female (16.7% vs. 39.3%, P = 0.03), and smokers (31.5% vs. 60.7%, P = 0.018) ( Table 4 ). In patients with BMI > 30, 27.2% experienced AKI versus 37.5% in patients with BMIr30. The last 6 patients treated in 2012 did not receive mannitol due to drug shortage. Four of these patients (66%) experienced AKI (P = 0.015) (data not shown). Of the 28 patients with AKI, 11 (39%) had op-HD-cis deviations (reasons: the AKI event [5] , neutropenia [4] , sepsis [1] , noncompliance [1] ; details in Supplemental Digital Content 3, http://links.lww.com/AJCO/ A128; Table 2 ).
AKI Following First Op-HD-Cis Cycle
Of 82 patients who received 1 op-HD-cis cycle, 20.7% experienced AKI after cycle 1 (Table 3) . Patients who developed AKI had significantly lower mean baseline SCr (0.76 vs. 0.89, P = 0.003) and significantly higher baseline eGFR (101.7 vs. 92.1, P = 0.015). Baseline BMI (P = 0.06) and weight (P = 0.09) were borderline significant (Table 4) . Patients with no AKI were, on an average, 9.60 kg heavier. Peak SCr occurred 6.9 and 8.3 days after op-HD-cis for those without and with AKI (P = 0.07).
AKI Following Second and Third Op-HD-Cis Cycles
Of 71 patients who received at least 2 op-HD-cis, 14% developed AKI after cycle 2. Patients who developed AKI were more often African Americans (AA) (4.9% vs. 40%, P = 0.006) and female (19.7% vs. 50%, P = 0.05) ( Table 4) . Of 19 patients who received 3 op-HD-cis, 21% developed AKI after cycle 3. Average peak SCr occurred at day 5.34 (cycle 2) and 6.8 (cycle 3), with no significant difference between groups.
CKD Analysis
CKD at Last Follow-up Visit
Sixty-eight patients had a median follow-up of 25.7 months (range, 3 to 60 mo). Average dose of cisplatin was 225.6 mg/m 2 and median dose was 200 mg/m 2 (95% confidence interval, 215-236). Median decrease in last eGFR was 12.3 mL/min/1.73 m 2 (interquartile range = 0.7 to 21.9) and mean ± SD decrease was 12.6 ± 18.6 mL/min/1.73 m 2 (Table 3) . Average amount of hydration (including that administered using op-HD-cis protocol) was 16.1 L (range, 5 to 43.5 L; SD = 7.2) and average amount of magnesium sulfate was 47.4 g (range, 16 to 192 g; SD = 34.5).
Five (7.3%) patients had the last eGFR below 60 mL/min/ 1.73 m 2 and in 3 (4.4%) patients this was attributed to op-HDcis (last eGFR 58, 59, and 49 mL/min/1.73 m 2 ). Two patients developed comorbidities that likely contributed to development of CKD (hepatorenal syndrome and nephrectomy for renal cyst). No patient required renal replacement therapy. A total of 19.1% patients had decrease in last eGFR of Z25% from baseline (Table 3) .
Adjusting for duration of follow-up, patients with higher baseline eGFR (P = 0.007) and lower baseline SCr (P = 0.01) had larger decrease in eGFR after treatment. These patients required significantly more hydration and Mg replacement (P = 0.008 and 0.04, respectively). AAs, smokers, and patients with lower baseline weight had greater decline in eGFR, approaching statistical significance (P = 0.06, 0.10, and 0.06, respectively) ( Table 5 ).
CKD at 1-Year Posttreatment
Fifty-five of 68 patients had SCr data available at 1 year (range, 8 to 14 mo; average, 11.4 mo; 11 patients had follow-up of <8 mo and 2 patients were noncompliant with scheduled evaluation in the 8 to 14 mo timeframe). For those patients, the median decrease in 1-year eGFR was 8.7 (interquartile range = 0.7 to 21.9) and the mean ± SD was 12.2 ± 17.7 (Table 3) . Average dose of cisplatin was 227.1 mg/m 2 and median was 200 mg/m 2 (95% confidence interval, 215.3-238.9). The same 5 patients with decline in last eGFR below 60 mL/min/1.73 m 2 had similar 1-year eGFR levels. Eighteen percent of patients experienced decrease in 1-year eGFR of Z25%. Figure 1B presents the 1-year eGFR relative to baseline eGFR for each patient. Females (P = 0.04), smokers (P = 0.003), hypertensives (P = 0.04), and those requiring more Mg replacement (P = 0.04) had significantly greater decline in 1-year eGFR (Table 5 ). There was no significant correlation between patients who developed AKI during treatment and patients who had decline in eGFRZ25% at 1 year (P = 0.17) or at last follow-up (P = 0.52).
Electrolytes and BUN/Cr During Treatment and at 6 Months Posttreatment
Electrolytes and BUN/Cr were analyzed in 68 patients with at least 2 op-HD-cis administrations. Cycle 3 was not analyzed due to small sample size. Average levels of Na, K, and Mg were significantly lower after each cycle. At 6 months, all patients had normalized K, 7 patients maintained borderline low Na (131 to 134 mmol/L), and only 2 patients maintained borderline low Mg of 1.7 mg/dL. Expectedly, the percentage of patients with BUN/CrZ20 was high following each op-HDcis (88.2% and 80.6%), but decreased to pretreatment level within 6 months (35.3%) (Supplemental Digital Content 4, http://links.lww.com/AJCO/A129; Table 3 ).
DISCUSSION
This retrospective study analyzes an op-HD-cis regimen aimed at preventing acute and chronic kidney toxicity in SCCHN patients. It is particularly challenging for patients with SCCHN receiving CRT to maintain adequate hydration. Oropharyngeal mucositis leads to dysphagia, nausea, and vomiting, yet maintaining adequate hydration is the main method to prevent cisplatin nephrotoxicity. [8] [9] [10] [15] [16] [17] [18] Poor nutritional and hydration status at time of diagnosis can further increase the risk of AKI. Our op-HD-cis protocol uses close monitoring and supplementation of fluids and electrolytes, facilitated by daily visits for RT. Initial "preventive" rigorous hydration regimen addresses the first 96 hours demonstrated to be a vulnerable period for development of kidney toxicity. 14, 19, 22 The second "responsive" phase, represented by replacement of water and electrolytes as needed, is of equal importance in the SCCHN population.
Large prospective studies involving similar patient populations treated with HD-cis concurrent with RT report on nephrotoxicity; however, limited information is provided to allow for protocol comparisons, underscoring the need for a consistent method of measuring and reporting chemotherapy-induced nephrotoxicity. We analyzed nephrotoxicity utilizing KDIGO criteria and provided results compatible with other measurement methods reported in literature as exemplified below.
Approximately one third of our participants experienced at least 1 AKI event during chemotherapy as defined by KDIGO criteria. If AKI was defined by increase in Cr above normal level for the measuring laboratory, the incidence would be 21%. These results are comparable with inpatient hydration regimens. A retrospective study evaluating 62 patients with SCCHN treated inpatient with cisplatin and 5-fluorouracil with concurrent radiation-reported nephrotoxicity incidence of 37% after first cycle and 46% after 1 or 2 cycles. 10 Nephrotoxicity was defined in this study as an increase in SCr by >0.5 mg/dL from baseline. Using the same definition of AKI, our results compare favorably with an incidence of nephrotoxicity of 14.6% after cycle 1 and 28.1% after 1 or 2 cycles. In a large prospective randomized study, 26 late kidney toxicity was measured by Cr level and graded according to Radiation Therapy Oncology Group Common Toxicity Criteria. Reported incidence of grade 1 or more toxicity (Cr level above 1.5 Ânormal) was 18%. We report only 2 findings of grade 1 toxicity measured by the same criteria, and these events were found in 2 patients who developed renal comorbidities within the first year of CRT. In another retrospective report of SCCHN patients treated with HD-cis concurrent with RT, higher incidences of AKI (53.7%) and CKD (29.6%) were reported. 27 It was not clear whether HD-cis was given as outpatient or inpatient. In addition, stricter criteria for AKI and a different formula to calculate Cr clearance and define CKD were utilized, precluding direct comparisons. Previous reports showed that 25% to 35% of patients with various malignancies treated with single-dose cisplatin infusion develop a decrease in GFR. 8, 28 Moreover, a persistent reduction in GFR by 20% to 30% was shown in long-term follow-up studies 28 and irreversible renal damage was reported in about a third of patients. 6 The CKD-EPI formula was elected to estimate GFR in study patients given that baseline SCr was within normal limits. With a median follow-up of 25.7 months, the average decrease in eGFR was 12.57 mL/min/1.73 m . 28 We reported an incidence of eGFR decline by Z25% comparative to baseline in 19.1% of patients at last follow-up and 18% of patients eligible for 1-year evaluation. The incidence of mild-moderate CKD per KIDGO criteria in our study was 5.4% at 1 year and 4.4% at last follow-up.
Although there is a consistent theme in the literature about cisplatin nephrotoxicity leading to cisplatin dose limitation, 8, 9, 29, 30 we reported only 6.1% of patients having chemotherapy changes caused by nephrotoxicity. In our series, deviations from scheduled op-HD-cis were caused primarily by neutropenia, then mucositis, and lastly by AKI. AKI did not seem to be associated with other complications that led to treatment alterations: mucositis did not cause cisplatin changes in any patients with AKI, and neutropenia caused similar alterations in patients with or without AKI (14.3% vs. 13%). Further, there was no significant correlation between patients with any AKI and patients with eGFR drop Z25%. These findings support the efficacy of our op-HD-cis protocol.
Our protocol incorporated early SCr and electrolytes monitoring with scheduled hydration. In this context, SCr nadir was on average 1 week posttreatment with a wide range (2 to 18 d). This finding underlines the importance of scheduling weekly follow-up assessments of kidney function with embedded time for hydration and electrolytes replacement as needed. Mg wasting has been reported as the most common electrolyte abnormality during treatment with cisplatin. 11 Moreover, long-lasting hypomagnesemia has been reported after treatment with cisplatin, up to 10 years. 31, 32 In our study, all but 2 patients had Mg levels within normal limits at 6 months posttreatment, raising the hypothesis that adequate early Mg replacement might prevent later losses.
In our analysis, patients with low baseline SCr and high eGFR were significantly more susceptible to AKI. These patients had significantly lower baseline weight and BMI. We believe that this correlation is an artifact of apparently low SCr due to weight loss with decreased muscle mass and low protein intake that patients often experience before cancer diagnosis. wPatients who were currently smoking and those who had been quit for <1 year were considered current smokers. zIn addition to hydration protocol. 1-year REL-eGFR indicates observed relative percent change in eGFR at 1-year evaluation; BMI, body mass index; BUN, blood urea nitrogen; CKD, chronic kidney disease; Cr, creatinine; eGFR, estimated glomerular filtration rate; IV, intravenous; last REL-eGFR, observed relative percent change in eGFR at the last followup evaluation; Mg, magnesium; N, number; r, correlation; SCr, serum creatinine; SE, standard error.
During cycle 1, patients that did not experience AKI were, on average, 9.6 kg heavier than patients who did (P = 0.09) with a difference in BMI close to statistical significance (P = 0.06). Patients with BMI > 30 had fewer AKI events despite cisplatin dose being calculated based on actual body weight. This finding should caution against misinterpretation of a low SCr level, especially in a patient with low BMI and weight, which could lead to inadequate hydration and kidney function monitoring. In a multivariate regression analysis, weight, SCr, and eGFR lost statistical significance for association with AKI or CKD preventing definite conclusions (data not shown).
Similar with other studies, female sex, smoking, and AA race were associated with worse kidney outcomes. 5, 10 Although statistical significance was not reached in all AKI analyses, it is important to underline that 6 of 8 AA patients presented at least 1 AKI event during treatment, with statistical significance reached for the independent analysis of cycle 2 (P = 0.006). Similar predictors of AKI correlated with worse long-term outcome of kidney function defining progressive CKD: current smoking status, AA race, female sex, initial lower weight, SCr, and higher eGFR. In addition, patients with hypertension expectedly had a greater decline in eGFR at 1 year (P = 0.04).
Several studies showed that statins 32, 33 could protect against cisplatin-induced nephrotoxicity. Approximately a quarter of patients took statins; however, there was no protective effect on AKI or CKD.
The efficacy of osmotic diuretics, in particular mannitol, for preventing nephrotoxicity remains unclear. 4, 9, 18, 20, 34 Our initial protocol included mannitol; however, it was not received by 6 patients due to supply shortages. Unexpectedly, 4 of the 6 patients had AKI during treatment (66% vs. 31.5% in patients treated with mannitol). This is a low number of patients but revives old controversies.
Our study describes an op-HD-cis protocol, and our findings, although retrospective and obtained using calculated eGFR as opposed to more precise direct measurements of the true glomerular filtration, show limited early and late nephrotoxicity in SCCHN patients treated with CRT. Importantly, nephrotoxicity was not the main dose-limiting toxicity. Our results emphasize the importance of close monitoring and additional hydration and electrolyte replacement as needed. Low baseline SCr in patients with low body weight should not decrease the protocol intensity. Future effort is needed in consistently measuring and reporting chemotherapy-induced nephrotoxicity.
